Study Finds Mannatech’s Ambrotose AO Product Increases Resting Blood Antioxidant Capacity

Printer-friendly versionPDF version

New findings published in “Nutrition Journal”

(COPPELL, Texas) Dec. 1, 2010-

Mannatech, Incorporated

(NASDAQ:MTEX-

News), a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced the results of a newly published randomized, double-blind placebo-controlled crossover study printed in

Nutrition Journal

that demonstratesAmbrotose AO®  capsulestaken at the daily dosage of four capsules per day increases resting blood antioxidant capacity and may enhance post exercise antioxidant capacity.* †

“Mannatech’s Ambrotose AO capsules are formulated with precise levels of water soluble and fat soluble antioxidants. It is now one of the most scientifically validated antioxidant products available to consumers,” said

Mannatech’s Co-CEO and Chief Science Officer, Robert A. Sinnott, MNS, Ph.D.

“This newly published study confirms the effectiveness of Mannatech’s proprietary Ambrotose AO product for diminishing the effects of oxidative stress in the human body.”

In this 21-day independent human study,Dr. Richard J. Bloomerand scientists from theUniversity of Memphisshowed Ambrotose AO capsules (four capsules/day for three weeks) significantly increased two measures of antioxidant capacity — Oxygen Radical Absorbance Capacity (ORAC) and Trolox Equivalent Antioxidant Capacity (TEAC) — in the blood of 25 healthy  men and women at rest.* Compared to placebo, Ambrotose AO capsules also caused a greater increase in blood ORAC at 30 minutes post-exercise.*  

The results further validate thestudypreviously published in May byDr. Stephen P. Myersconducted in Australia for five weeks on 21 healthy adults that showed four capsules per day of Ambrotose AO dietary supplement was safe and raised serum Oxygen Radical Absorbance Capacity ORAC.* 

To ensure that adequate amounts of antioxidants are included in your diet, Dr. Sinnott offers the following tips:

• For the best antioxidant protection under all conditions, you should have both fat-soluble and water-soluble antioxidant compounds in proper amounts. Your body has both aqueous (water-based) and lipid (fat-based) components and they both need protection from oxidative stress.
• Fresh fruits and vegetables are usually good sources of natural antioxidants, but if you do not eat at least five to nine servings a day, you may want to include a high quality antioxidant dietary supplement daily.
• Don’t be fooled by high “ORAC” values touted on some product labels or marketing materials. These values are often calculated from laboratory experiments and do not necessarily translate to health value since some antioxidants are not absorbed into the body.
• Overdoing anything is generally not a good idea, antioxidants included. Taking too much of an antioxidant can actually cause it to become a pro-oxidant and cause oxidative stress. Stay away from “megadose” antioxidant products and choose an antioxidant with published human clinical studies showing health benefits.

Currently, Mannatech holds more than 45 patents in 30 countries for the technology related to Ambrotose complex. In addition, many of Mannatech’s products are based on

Real Food Technology^SM

solutions, which provide consumers with products that contain standardized levels of natural and plant-sourced nutrients. Food-sourced ingredients are chosen from those scientifically proven to most benefit the human body.

For technical information about Mannatech’s products and scientific research publications, visit

MannatechScience.org

. Individuals interested in Mannatech’s products or in exploring its business opportunity can learn more at

Mannatech.com

.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. These proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore and the Republic of Korea. For more information, visitus.mannatech.com.

Please Note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

* This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

† Mannatech, Incorporated funded both studies and donated the Ambrotose products used in each study.

News Source : Study Finds Mannatech’s Ambrotose AO Product Increases Resting Blood Antioxidant Capacity